ERBB2 and breast cancer: The eight-gene RD signature was subsequently subjected to survival analysis using mean expression for the eight genes in each subject, which revealed significant predictive power for this signature on RFS (Figure 2d) and OS (Figure 2e) for basal and HER2+ breast cancer, but not for those with Luminal A and Luminal B tumors.